Fate Therapeutics Q3 2022: Cash $519M, $15M revenue; FDA positive feedback on FT516 RMAT; pipeline progress

FATE THERAPEUTICS INC

2022-Q3 EPS reported -$2.33 revenue$51,944,000

Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.
Positive FDA feedback under FT516 RMAT for clonal master iPSC bank and potential registrational study design; CMC meeting set for December.
Enrollment ongoing for FT596+R three-dose escalation at 1.8B cells/dose for R/R BCL; activating community sites for FT596+R-CHOP in newly-diagnosed aggressive BCL.
Janssen exercised option for second iPSC-derived CAR NK product targeting undisclosed hematologic malignancy antigen; FT555 (GPRC5D) IND candidate for MM to be presented at ASH.
14 abstracts selected for ASH and 12 for SITC, including interim Phase 1 data for FT576 (MM), FT819 (BCL), FT536/FT538 (solid tumors).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

FATE THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0000950170-22-021834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.